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ABSTRACT 
Non-alcoholic fatty liver disease (NAFLD) is a disease with increasing prevalence 
worldwide, especially in developed countries. While the etiology of NAFLD is complex, the 
intestinal microbiome may play a role in the development of liver steatosis through bacterial-
induced inflammation. Lipopolysaccharide-binding protein (LBP) is an acute-phase protein 
produced by the liver and which facilitates bacterial-induced inflammation. LBP levels in the 
serum tend to be low but are raised during infection or in the presence of bacterial components; 
thus, levels of LBP are considered to be reflective of bacterial-induced inflammation. While the 
association of LBP with NAFLD has been investigated in cross-sectional studies, no longitudinal 
studies have been done to determine if LBP levels are associated with liver fat accumulation. 
Furthermore, no studies have been performed which show the heritability of LBP levels, which 
may affect susceptibility to the inflammatory response. Elucidation of the role of LBP in NAFLD 
can provide insights into the etiology of NAFLD and provide a mechanistic link between the 
intestinal microbiome and liver fat accumulation, yielding public health importance for the 
understanding and treatment of NAFLD. This study is the first longitudinal study to look at the 
associations of LBP with the development of steatosis and it is the first study to determine the 
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heritability of LBP in any population, thus supplying novel information on the associations 
between LBP and liver fat accumulation. 
A large family-based study of African ancestry men and women (N = 470) and a large 
prospective cohort study of African ancestry men (N = 2853) from Tobago were used for this 
study. LBP was measured in all individuals in the family study. Heritability analyses were 
performed using SOLAR. In the prospective cohort study, LBP levels were measured at baseline 
visit (2004-2007), and liver fat was assessed at the follow-up visit (2013-2016, ~10 years later) by 
computerized tomography (CT) scan, with an overlap of 204 men having both LBP and liver CT 
completed. Associations were assessed using Spearman correlations and regression analyses. LBP 
levels in the families were found to have no residual heritability, suggesting that LBP might be 
entirely environmentally determined in this population. In the prospective cohort, LBP was 
associated with liver fat infiltration in multivariable analyses which included BMI (p = 0.0469), 
but not in models which instead included waist circumference. In conclusion, we determined that 
among African ancestry individuals, LBP levels are completely environmentally determined and 
that levels may be associated with increases in liver fat accumulation. 
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1.0  INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is defined as the buildup of hepatic fat in the 
absence of heavy alcohol drinking1. NAFLD is extremely common, with a worldwide prevalence 
rate of 6%–35% and a median of 20%2. NAFLD serves as an umbrella term for a spectrum of liver 
disease, ranging from the relatively benign non-alcoholic fatty liver (NAFL) to non-alcoholic 
steatohepatitis (NASH), which can lead to cirrhosis and liver cancer1. NAFLD is associated with 
many of the components of metabolic syndrome and so is thought to be the manifestation of 
metabolic syndrome in the liver3,4. In addition, individuals with NAFLD are at increased risk of 
developing type 2 diabetes and cardiovascular disease4. 
Pathogenesis and progression of NAFL and NASH are complex and not currently not clear, 
involving a complex interplay between diet, genetics, insulin resistance, adipose tissue and 
inflammation3-5. One hypothesis of progression to NASH is the “two-hit hypothesis”, where the 
first hit is the accumulation of fat in the liver and the second hit is either lipid peroxidation or 
cytokine-mediated injury leading to liver inflammation and fibrosis6. Of recent interest to the 
development of NAFLD is the role of the gut microbiota. In mouse models, the colonization of 
germ-free mouse intestines with bacteria was associated with a 2.3-fold increase in hepatic 
triglycerides with no changes in total liver free fatty acids or cholesterol7. Small intestinal bacterial 
overgrowth was more prevalent among NASH patients than in matched healthy controls8. 
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Additionally, individuals with NAFLD have been found to have greater intestinal permeability, 
and this is associated with NAFLD severity9. 
One method by which intestinal bacteria could impact NAFLD pathogenesis is through 
effects on systemic inflammation. Lipopolysaccharide (LPS) is a lipid constituent of the Gram-
negative bacterial membrane10. Bacteria shed LPS throughout their lifecycle, and this LPS can be 
absorbed in the intestinal tract and circulate through the body via the hepatic portal vein11. Once 
in the circulation, it has the potential to bind with the cell receptor toll-like receptor 4 (TLR4) and 
to initiate an inflammatory cytokine response12. Lipopolysaccharide-binding protein (LBP) is an 
acute-phase protein produced primarily by the liver and plays a role in LPS-induced 
inflammation11,13. LBP and LBP-like proteins are found widely across the animal kingdom and are 
thought to originate from a family of ancient lipid-binding proteins, and while a few residues are 
conserved across some species, most LBP proteins share common motifs14. LBP binds to LPS, 
complexes with protein CD14, and then transfers LPS to the TLR412. It has been demonstrated in 
mice that chronic LPS infusion promotes weight gain similar to eating a high fat diet15; 
additionally, obesity is commonly found to be associated with chronic low-grade inflammation16. 
Thus, it is believed that gut bacteria-derived LPS and subsequent transference by LBP is thought 
to be linked to systemic low-grade inflammation and inflammatory diseases. 
LBP has been associated with obesity, insulin resistance, and metabolic syndrome17-21. Due 
to the associations with metabolic syndrome, it is not surprising that LBP is also associated with 
NAFLD. Ruiz et al. demonstrated that, compared to healthy controls, obese patients with NASH 
had elevated levels of LBP, and individuals with NASH had higher levels of LBP than those with 
just steatosis. Additionally, the study showed that levels of LBP correlated with liver TNF-α 
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mRNA production22. A study by Wong et al. found in a prospective Chinese cohort that individuals 
with incident NAFLD had higher LBP levels at baseline23. 
Despite associations with NAFLD itself, it is controversial whether LBP is associated with 
liver fat progression or just with the other metabolic phenotypes often accompanying NAFLD. In 
the same study by Wong et al., it was seen in a larger cross-sectional group that LBP was positively 
correlated with intrahepatic triglycerides in a univariate analysis; however, the association with 
intrahepatic triglycerides became insignificant in a multivariable analysis23. Similarly, in a study 
of bariatric surgery patients with different severities of NAFLD, LBP was found to be higher in 
all NAFLD groups compared to lean healthy controls, but could neither discriminate between 
severities of NAFLD nor between those with normal liver and those with NASH/NASH fibrosis, 
indicating that it may only be tracking components of the metabolic syndrome in those 
individuals24. 
It is possible that LBP may only be associated with earlier increases in liver fat but may 
not play a role in later stages of NASH. It appears that no prospective studies have looked at LBP 
in relation to hepatic fat accumulation; rather, all studies have been cross-sectional or have only 
reported on incident cases of NAFLD and not on unit change in liver fat. Furthermore, studies 
looking at LBP and liver fat accumulation have not been performed in African ancestry 
populations. Thus, this study set out to determine if baseline levels of LBP could predict liver fat 
accumulation in an African ancestry population. 
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2.0  METHODS 
2.1 THE TOBAGO HEALTH STUDIES 
Between 1997 and 2003, 3,170 previously unscreened men were recruited for a population-
based prostate cancer screening study on the Caribbean island of Tobago, Trinidad and Tobago25. 
To be eligible, men had to be ambulatory, noninstitutionalized, and not terminally ill. Recruitment 
for the survey was accomplished by flyers, public service announcements, and posters, informing 
health care workers at local hospitals and health centers, and word of mouth. Approximately 60% 
of all age-eligible men on the island participated, and participation was similar across the island 
parishes. This group of age-eligible men served as the pool of potential probands for the Tobago 
Family Health Study and as the first visit of the Tobago Health Study (the men recruited and 
followed for the population cohort).  
Men in the Tobago health studies cohort are primarily of West African Ancestry, similar 
to African Americans. Genetic ancestry markers have determined ~94% West African ancestry in 
the Tobago population26. In addition to sharing West African ancestry, Tobagonian Afro-
Caribbean men and African American men also share similarities in skeletal muscle quality and 
body fat distribution27-31. However, low gene flow due to limited in-migration and out-migration 
from the island, as well as cultural differences as compared to the U.S. and Africa, make the 
Tobagonian men a unique and informative African Ancestry study population. 
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2.1.1 Study Population: Tobago Family Health Study 
Probands for the Tobago Family Health Study were identified from the Tobago Health 
Study. To be eligible, a proband had to be Afro-Caribbean (determined by self-report of having 
four Afro-Caribbean grandparents), have had a spouse who was willing to participate in the study, 
and have at least six living offspring and/or siblings aged 18+ years who were residing in Tobago. 
Probands and families were recruited without regard to health status, resulting in 7 
multigenerational families (mean family size N = 51) with 401 individuals spanning 18–103 years 
old (mean age = 43). Among the families, we have the following relationships: 361 parent–
offspring, 495 full siblings, 101 grandparent–grandchildren, 1,137 avuncular, 61 half-siblings, and 
1,380 cousins (3,535 relative pairs). All participants provided written informed consent. 
2.1.2 Study Population: Tobago Prostate Cohort Study 
Between 2004 and 2007, all men from the Tobago Health Study were invited to participate 
in a follow-up clinic examination. 2,031 men (70% of survivors) and 451 new participants 
completed the visit. This visit represented the baseline for the current study.  
Between 2014 and 2017, we invited these men to return for repeat clinical examinations 
and CT scans. The baseline and follow-up visits followed the same procedures for questionnaire 
interviews and biospecimen collection. The Institutional Review Boards of the University of 
Pittsburgh and the Tobago Ministry of Health and Social Services approved this study. All 
participants provided written informed consent before data collection. 
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2.2 STUDY-SPECIFIC VARIABLES: FAMILY STUDY 
2.2.1 Dual-Energy X-ray Absorptiometry Measures 
Dual-energy X-ray absorptiometry (DXA) measurement of total body adipose tissue was 
made using a Hologic QDR 4500W densitometer (Hologic Inc., Bedford MA). Scans were 
analyzed with QDR software version 8.26a. 
2.2.2 Anthropometric and Lifestyle Measurements 
Body weight was recorded to the nearest 0.1 kg without shoes on a balance beam scale. 
BMI was calculated from body weight and standing height (kg/m2). Information on lifestyle habits 
(smoking status [current/not current], minutes walked per week, and alcohol drinking [yes/no]), 
medication use, and post-menopausal status for women (yes/no), were assessed using standardized 
interviewer-administered questionnaires. Hypertension was defined as a systolic blood pressure 
(SBP) of ≥ 140 mmHg and/or diastolic blood pressure (DBP) of ≥ 90 mmHg. Type 2 diabetes was 
defined as fasting serum glucose ≥ 126 mg/dL and/or currently taking antidiabetic medication. 
2.3 STUDY-SPECIFIC VARIABLES: COHORT STUDY 
2.3.1 Liver CT Scans 
CT scanning of the liver was performed using dual slice, high-speed NX/I scanner, with 
gantry speed 0.7 seconds (GE Medical Systems, Waukesha, WI) to assess liver fat. CT images at 
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T12-L1 were obtained and used to measure the liver located below the right diaphragm 
corresponding to superior aspects of the right and medial lobes or hepatic segments 4a, 7 and 8 
using the Couinaud system. The analysts deposit 3 regions of interest (ROIs) within homogenous 
portions of the liver at two levels. Liver attenuation measured in Houndsfield units (HU) was 
calculated as the average density of three regions. CT scans were read at the Wake Forest 
University (WFU) Imaging Center and analyzed using Medical Image Processing, Analysis, and 
Visualization (MIPAV) software with custom programmed subroutines (a.k.a.“plug-ins”) coded 
at WFU Health Sciences (WFUHS). MIPAV is a software application produced by the National 
Institute of Health’s Center for Information Technology; Biomedical Imaging Research Services 
Section lead by Dr. Matthew McAuliffe32.  
2.3.2 Anthropometric, Lifestyle, and Medicinal Measurements 
Body weight was recorded to the nearest 0.1 kg without shoes on a balance beam scale. 
BMI was calculated from body weight and standing height (kg/m2). Waist circumference was 
measured at the narrowest point of the waist using an inelastic fiberglass tape. If there was no 
narrowest point, waist circumference was measured at the umbilicus. Information on lifestyle 
habits (smoking status [never/ever/current], hours walked per week, hours of television watching, 
and current intake of alcohol of more than 8 drinks per week [yes/no]), and medication use (non-
steroidal anti-inflammatory drugs [NSAIDs], anti-hypertensives, and antidiabetics) were assessed 
using standardized interviewer-administered questionnaires. Men were asked to bring all 
prescription medications taken in the past 30 days to their clinic visit. Participants also rated their 
overall health status compared with men their own age. Prediabetes was defined as having a fasting 
serum glucose level of 100–125 mg/dL without being on any antidiabetic medication.  Type 2 
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diabetes was defined as currently taking an antidiabetic medication, regardless of fasting serum 
glucose level, or having a fasting serum glucose level of ≥ 126 mg/dL. Hypertension was defined 
as a SBP of ≥ 140 mmHg and/or DBP of ≥ 90 mmHg and/or currently taking antihypertensive 
medication. Fatty liver disease was defined as HU < 40. 
2.4 SHARED STUDY VARIABLES: INFLAMMATION AND METABOLIC 
MARKERS 
All biochemical assays in fasting serum samples were performed in the Heinz Nutrition 
Laboratory at the University of Pittsburgh. Fasting serum glucose was measured using an 
enzymatic procedure; the coefficient of variation percentage (CV%) between runs was 1.8%. 
Insulin was measured using a radioimmunoassay procedure developed by Linco Research, Inc.; 
the CV% between runs was 2.1%. The degree of insulin resistance (IR) was estimated by 
homeostatic model assessment (HOMA) according to the method described by Matthews et al.33. 
In previous studies, HOMA-IR has correlated reasonably well with insulin clamp techniques34. 
High-density lipoprotein cholesterol (HDL-c) was determined using the selective 
heparin/manganese chloride precipitation method and had an inter-assay coefficient of variation 
(CV) of 2.1%. Low density lipoprotein cholesterol (LDL-c) was calculated by means of the 
Friedewald equation35. Triglycerides were determined enzymatically using the procedure of 
Bucolo and David36 and had an interassay CV of 1.7%. Baseline fasting serum LBP was measured 
using a Human LBP Enzyme-Linked Immunosorbent Assay (ELISA) kit (Cell Sciences, Canton, 
MA) according to the manufacturer’s protocol. Manufacturer-reported inter- and intra-assay CV% 
were 9.8%–17.8% and 6.1%, respectively.  
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2.5 STATISTICAL ANALYSES 
Heritability analyses were performed using the Sequential Oligogenic Linkage Analysis 
Routines (SOLAR) program. Two models were generated: one sex- and age-adjusted, and one 
where all covariates were screened and where only significant covariates were retained. The 
residual heritability (h2r) for LBP was estimated as well as the variance attributable to the fixed-
covariance effects (r2) for each of the additional variables. 
To be included in the cohort liver analysis, men must have fasted at least 8 hours prior to 
baseline interview blood draw, must have had LBP and lipids measured at the baseline visit, and 
must have had liver CT scans analyzed at the follow-up. 1385 men had lipids measured, 582 men 
had LBP measured at baseline, and 550 men had liver CT scans analyzed at follow-up; overlap 
between these two populations was 199 individuals who were eligible for analysis. One individual 
was found to have fasted < 8 hours and so was dropped from analysis. One individual  
was also found to have an outlier >3 standard deviations from the mean in LBP and was dropped 
from analysis; two individuals had missing LBP values. This resulted in a final sample size of 195 
for analysis. 
Associations between liver attenuation and other variables were determined using 
Spearman correlations. For multiple linear regression analyses, liver attenuation was cube-
transformed to normalize the residuals. Multiple logistic regression models were constructed to 
examine one of two outcome variables: (1) dichotomizing liver attenuation values based on the 
median liver attenuation value and (2) membership in the highest and lowest quartiles of liver 
attenuation value. Statistical significance was based on an α = 0.05, and analyses were performed 
using SAS 9.3 software (SAS Institute, Inc., Cary, NC). 
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3.0  RESULTS 
3.1 HERITABILITY OF LBP 
3.1.1 Family Study Population Characteristics 
Population characteristics of the families can be found in Table 1. Participants on average 
were 42 years of age and were slightly overweight with a median BMI of 27.55 kg/m2. They were 
relatively healthy with low rates of drinking (13.22%) and smoking (4.91%) and with low rates of 
hypertension (28.63%) and type 2 diabetes (15.84%). 
3.1.2 Results of Heritability Analysis 
In the age- and sex-adjusted models, the heritability of LBP was extremely low and non-
significant (h2r = 0.067, p = 0.237), and the proportion of variance due to age and sex was 0.0483. 
A second model was generated in which all covariates (all variables listed in Table 1; excluded 
BMI from analysis since trunk fat was used) were tested but only significant covariates were 
retained (age, trunk fat, alcohol drinking category, menopause status, HDL-c, and walking); in this 
model, LBP was not heritable (h2r = 0.000, p = 0.500), and the proportion of variance due to the 
covariates was 0.142. 
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Table 1. Family Study Population Characteristics 
Variable N Median (IQR) or N (%) 
General Characteristics   
Age (years) 471 42 (28, 54) 
Sex (Female) 471 284 (60.30) 
Post-Menopausal  463 88 (19.01) 
BMI (kg/m2) 466 27.55 (23.48, 31.95) 
Trunk Fat (kg) 444 10.03 (6.296, 13.92) 
DBP (mmHg) 461 74 (67, 82.67) 
SBP (mmHg) 461 116.67 (105.33, 138.67) 
   
Lifestyle Factors   
Walking (min/week) 466 20 (0, 60) 
Drink Alcohol 469 62 (13.22) 
Current Smoker 468 23 (4.91) 
Hypertensive 461 132 (28.63) 
Type 2 Diabetes 461 73 (15.84) 
   
Metabolic Measures   
HDL-c (mg/dL) 397 39.20 (31.10, 48.50) 
LDL-c  (mg/dL) 398 127.55 (104, 157.90) 
Triglycerides (mg/dL) 401 77 (59, 104) 
HOMA-IR 394 2.77 (1.95, 4.17) 
LBP (µg/mL) 462 25.04 (17.68, 34.61) 
       IQR = Interquartile Range 
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3.2 LBP AND LIVER FAT 
3.2.1 Cohort Population Characteristics 
General baseline characteristics of men in the cohort are reported in Table 2. Men in the 
longitudinal cohort were relatively young with a median age of 53. They were slightly overweight 
(median BMI = 27.03 kg/m2), and about half were hypertensive (54.36%). Incidence of NAFLD 
at follow-up was low (4.10%). 23.59% of the men were prediabetic and about 15% diabetic at 
baseline. 
 As can be seen in the population comparison table (Appendix Table 8), compared to the 
overall baseline population, the analyzed men were slightly healthier (lower levels of drinking, 
lower levels of current smoking, fewer type 2 diabetics, less medication usage, and greater 
perception of good health status). LBP values were similar between the analyzed cohort and the 
582 men in which LBP was measured; similarly, mean liver attenuation was similar between the 
analyzed cohort and the men in which liver CTs had been analyzed. 
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Table 2. LBP/Liver Cohort Population Characteristics 
Variable Median (IQR) or N (%) 
LBP (µg/mL) 20.89 (16.30, 27.11) 
Mean Liver Attenuation (HU) 59.36 (54.69, 61.87) 
Age (years) 53 (48, 64) 
Waist Circumference (cm) a  91 (84.3, 98) 
BMI (kg/m2) 27.03 (24.59, 29.56) 
Lifestyle  
Hours Walked per Week b 1.5 (0, 5) 
TV Watching (≥ 14 hrs/week) c 67 (34.54) 
Previous Smoker 39 (20) 
Current Smoker 10 (5.13) 
Any Alcohol Consumption 113 (57.95) 
4+ Alcoholic Drinks / Week 14 (7.18) 
8+ Alcoholic Drinks / Week 7 (3.59) 
Comorbidities  
SBP (mmHg) 139 (126, 154) 
DBP (mmHg) 80 (73, 89) 
Hypertension 106 (54.36) 
Prediabetic 46 (23.59) 
Diabetic 29 (14.87) 
HOMA-IR 2.75 (1.85, 4.11) 
HDL-c (mg/dL) 48 (41.10, 57.10) 
LDL-c (mg/dL) 134.50 (103.10, 162.20) 
Triglycerides (mg/dL) 103 (77, 131) 
Fatty Liver Disease 8 (4.10) 
Perceived Good Health 183 (94.33) 
Medication Use  
Antihypertensive Medication 42 (21.54) 
Antidiabetic Medication 19 (9.74) 
NSAIDs Medication 13 (6.67) 
a,b,c: Variables that had less than N = 195. Waist circumference, N = 193. Walking, N = 191. TV watching, 
N = 194. Abbreviation: TV = Television. 
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3.2.2 Correlation Analyses 
Spearman correlations were calculated between covariates and mean liver attenuation 
values. The lower the attenuation value, the higher the liver fat content; thus, inverse correlations 
are interpreted as an increase in liver fat for every unit increase in the variable. 
LBP, BMI, waist circumference, insulin resistance, triglycerides, diastolic blood pressure, 
and anti-hypertensive medications were all significantly and negatively correlated with mean liver 
attenuation, while HDL was significantly and positively correlated (Table 3). The association 
between LBP and mean liver attenuation was then determined after adjustment for the other 
covariates. For this analysis, hypertensive status was not included as a covariate (as SBP and DBP 
were in the model), and the model was run twice using either BMI or waist circumference. After 
adjustment for the other covariates, the association between LBP and increases in liver fat were 
attenuated but remained significant in both models (BMI adjusted model: N = 190, ρ = −0.182, p 
= 0.0158; waist-circumference adjusted model: N = 188, ρ = −0.174, p = 0.0223).    
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Table 3. Spearman Correlations with Mean Liver Attenuation 
Variables ρ p 
LBP (µg/mL) −0.20 0.0043 
Age (years) 0.04 0.5479 
BMI (kg/m2) −0.37 < 0.0001 
Waist Circumference (cm) a −0.37 < 0.0001 
HOMA-IR −0.29 < 0.0001 
HDL-c (mg/dL) 0.24 0.0006 
LDL-c (mg/dL) −0.09 0.2121 
Triglycerides (mg/dL) −0.21 0.0026 
Walking (hr/week) b 0.001 0.9924 
TV (≥ 14 hrs/week) c 0.07 0.3376 
Alcohol 8+ 0.10 0.1689 
Smoking Status 0.07 0.3102 
Hypertension −0.06 0.3822 
DBP (mmHg) −0.15 0.0362 
SBP (mmHg) −0.07 0.3694 
Anti-diabetic Use −0.13 0.0736 
NSAID Use −0.09 0.2309 
Anti-hypertensive Use −0.15 0.0328 
a,b,c: Variables that had less than N = 195. Waist circumference, N = 193. 
Walking, N = 191. TV watching, N = 194 
 
3.2.3 Linear Regression 
A simple linear regression analysis was performed between LBP and mean liver 
attenuation. Mean liver attenuation was very heavily left-skewed, resulting in non-normally 
distributed residuals (Figure 1). Therefore, a cube-transformed liver value was used for all linear 
regression analyses, which corrected this distribution. In the univariable model, LBP was 
significantly associated with having higher liver fat values at followup (β = −11.5, p = 0.0071). 
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Figure 1. Quantile-Quantile Plot and Histogram of Residuals 
 
Multivariable linear regressions were then performed (Tables 4). Importantly, waist 
circumference is thought to be more important for liver fat accumulation than general obesity37; 
however, with our small sample size and with waist circumference having been measured in two 
fewer individuals than BMI, any reduction in sample size could reduce power; thus, two analyses 
were performed, with models differing only in the use of BMI or waist circumference.   
In both models, no variance inflation or collinearity was detected according to diagnostics 
run in SAS. In the BMI model, the adjusted R2 was 0.184. In this model, mean liver attenuation 
was negatively associated with LBP (p = 0.0469) and BMI (p = 0.0006), indicating that increasing 
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LBP and BMI are associated with increases in liver fat. Interestingly, mean liver attenuation was 
almost statistically significantly and positively associated with heavy drinking (p = 0.0501); 
however, the standard error and confidence intervals are large, likely due to the very low number 
of heavy drinking in this population.  
In the waist circumference model, the adjusted R2 was 0.171. Mean liver attenuation was 
only significantly and negatively associated with waist circumference (p = 0.0023) but not 
significantly with LBP (p = 0.0547). Additionally, heavy drinking was significantly and positively 
associated with mean liver attenuation (p = 0.0226), indicating that those who drank the most in 
this population were protected from liver fat accumulation. Again, the standard error and 
confidence intervals were quite large for this estimate due to the low number of heavy drinkers. 
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Table 4. Linear Regression Models 
Baseline 
Variable 
Model with BMI 
(N = 190) 
Model with Waist Circumference 
(N = 188) 
β (SE) 95% CI p β (SE) 95% CI p 
LBP (µg/mL) −10.36 (8.22) (−13.03, −2.49) 0.0469 −10.30 (8.27) (−13.02, 2.81) 0.0547 
Age (years) 7.55 (7.94) (−8.24, 11.24) 0.3927 8.42 (7.98) (−7.41, 11.70) 0.2424 
BMI (kg/m2) −16.38 (10.78) (−19.00, −12.43) 0.0006 — — — 
WC (cm) — — — −11.44 (7.85) (−13.49, −8.16) 0.0023 
HOMA-IR −12.33 (13.58) (−18.96, 14.54) 0.4556 −13.43 (13.62) (−19.50, 13.69) 0.3392 
HDL-c 
(mg/dL) 
5.66 (7.45) (−8.59, 9.99) 0.6610 5.48 (7.50) (−8.73, 9.99) 0.6961 
LDL-c 
(mg/dL) 
1.06 (4.70) (−5.89, 5.91) 0.9908 −2.44 (4.72) (−6.05, 5.78) 0.8895 
Triglycerides 
(mg/dL) 
−4.78 (4.59) (−6.69, 4.34) 0.2605 −4.58 (4.62) (−6.63, 4.62) 0.3316 
DBP (mmHg) −7.24 (8.65) (−11.83, 9.64) 0.5576 −7.30 (8.71) (−11.92, 9.71) 0.5571 
SBP (mmHg) 6.51 (7.33) (−7.94, 10.17) 0.4841 5.89 (7.40) (−8.41, 10.01) 0.6147 
Drink 8+ 35.99 (28.70) (−3.13, 45.36) 0.0501 38.23 (28.95) (19.95, 46.99) 0.0226 
Walking 
(hr/week) 
5.38 (9.85) (−12.01, 12.69) 0.8712 −3.98 (9.88) (−12.53, 12.26) 0.9479 
Smoking 
Status 
17.94 (19.97) (−21.51, 27.81) 0.4693 19.50 (20.13) (−20.55, 28.65) 0.3645 
TV (≥ 14 
hrs/week) 
13.23 (21.17) (−25.41, 27.61) 0.8077 10.87 (21.32) (−26.13, 27.33) 0.8948 
Anti-diabetics −22.45 (25.27) (−35.08, 27.38) 0.4839 −24.47 (25.43) (−36.12, 26.12) 0.3744 
NSAIDs 7.02 (26.58) (−33.24, 33.45) 0.9853 10.67 (27.09) (−33.63, 34.33) 0.9514 
Anti-
hypertensives 
−26.06 (22.84) (−34.54, 17.99) 0.1393 −24.09 (23.01) (−33.63, 21.59) 0.2526 
Abbreviations: SE = Standard Error, WC = Waist Circumference. 
 
In observing the regression diagnostics, it was noticed that there were several influential points as 
determined by Cook’s D > 0.02 (Figure 2). To investigate these further, a plot of studentized r2 by 
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leverage for each observation was created (Figure 3). An r2 > 4 and a leverage hi > 0.17 were used 
as criteria for determining points which had potentially problematic residual values and whose 
leverage may affect the regression model. Following these criteria, two observations were found 
which could be problematic.  
 
 
 
Figure 2. Cook's D Plot of Influential Points 
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Figure 3. Residual Squared by Leverage Plot 
 
The two observations found in the above analysis were inspected further to determine 
what was driving their influence and to determine if they should be dropped from the analysis 
(Table 5). For each individual, covariate values and DFBETA (the amount that observation 
contributes to the standard error of the estimate) was listed. In the first individual, ID = 
TP990981VM, the BMI was higher than most men and most influence on an estimate (DFBETA 
= −0.7008); additionally, mean liver attenuation was very low compared to most men. However, 
these values were not likely to be errors, and therefore the participant should not be dropped 
from analysis. The second participant had no outstanding values but was one of the individuals 
who was a heavy drinker, which may be the reason for his being flagged. It was therefore 
determined that this participant should also not be dropped from the analysis. 
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Table 5. Influential Participant Characteristics and DFBetas 
TP990981VM  TP993112SV 
Variable Value DFBETA  Variable Value DFBETA 
LBP (µg/mL) 14.72 0.15  LBP (µg/mL) 22.20 0.21 
Age (years) 50 −0.02  Age (years) 49 −0.08 
BMI (kg/m2) 40.21 −0.70  BMI (kg/m
2) 26.30 0.36 
HOMA-IR 6.49 −0.24  HOMA-IR 8.81 −0.68 
HDL-c (mg/dL) 65.50 −0.49  HDL-c (mg/dL) 45.40 0.38 
LDL-c (mg/dL) 92.70 0.25  LDL-c (mg/dL) 173.60 −0.05 
Triglycerides 
(mg/dL) 79 0.12  
Triglycerides 
(mg/dL) 85 0.38 
DBP (mmHg) 79 0.07  DBP (mmHg) 93 0.25 
SBP (mmHg) 124 0.24  SBP (mmHg) 168 −0.37 
Drink 8+ No 0.12  Drink 8+ Yes −1.09 
Walking (hr/week) 10 −0.13  Walking (hr/week) 7 −0.08 
Smoking Status Ever −0.39  Smoking Status Never 0.24 
TV (≥14 hrs/week) No 0.07  TV (≥14 hrs/week) Yes −0.07 
Anti-diabetics No 0.32  Anti-diabetics No 0.11 
NSAIDs No 0.26  NSAIDs No 0.12 
Anti-hypertensives Yes −0.53 
 
Anti-hypertensives No 0.17 
Mean Liver 
Attenuation (HU) 18.54 — 
 Mean Liver 
Attenuation (HU) 49.65 — 
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3.2.4 Logistic Regression 
Two sets of logistic regression analyses were performed to determine if LBP could predict 
categorization by liver fat values at follow-up. The first set divided the population into high/low 
based off the median liver attenuation value, 59.3553 HU. Two logistic regression models were 
again done, using BMI or waist circumference (Table 6). In the univariable analyses, 97 people 
had liver attenuations below the median and 98 had liver attenuations above the median. In the 
multivariable analyses, the population was split 95 above the median and 95 below. Only baseline 
LBP (OR = 1.063, 95% CI: 1.017–1.112) and BMI (OR = 1.228, 95% CI: 1.091–1.382) could 
significantly predict being in the top 50% of fatty livers. In the waist circumference model, the 
population was split with 95 above the median and 93 below. Again, only baseline LBP (OR = 
1.059, 95% CI: 1.014–1.106) and waist circumference (OR = 1.059, 95% CI: 1.014–1.106) could 
significantly predict being in the top 50% of fatty livers.  
Mean liver attenuation was then divided into quartiles. Logistic regression analysis was 
run to determine if LBP could predict being in the highest liver fat quartile (mean liver attenuation 
≤ 54.6946 HU) versus the lowest liver fat quartile (mean liver attenuation ≥ 61.8709 HU) (Table 
7). In univariable analyses, 48 people were in the high-fat quartile and 49 in the low-fat quartile. 
In multivariable analyses, 46 people were in the high-fat quartile and 49 in the low-fat quartile. 
Similar to the median-based analysis, in the BMI model only LBP (OR = 1.106, 95% CI: 1.019–
1.200) and BMI (OR = 1.336, 95% CI: 1.087–1.642) could significantly predict high-fat quartile. 
In the WC model, only LBP could significantly predict high/low fatty liver quartile (OR = 1.089, 
95% CI: 1.008–1.176). 
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Table 6. Logistic Regression (Median)  
Baseline 
Variable 
Univariable Analysis 
(N = 195) 
 
Multivariable Analysis 
(BMI, N=190) 
 
Multivariable Analysis 
(WC, N = 188) 
 
OR 
(95% CI) p 
OR 
(95% CI) p 
OR 
(95% CI) p 
LBP 
(µg/mL) 
1.06 
(1.02, 1.10) 0.0025 
1.06 
(1.02, 1.11) 0.0072 
1.06 
(1.01, 1.11) 0.0101 
Age (years) 1.00 (0.98, 1.03) 0.9043 
1.01 
(0.97, 1.05) 0.5793 
1.00 
(0.96, 1.04) 0.9538 
BMI (kg/m2) 1.23 (1.13, 1.34) <.0001 
1.23 
(1.09, 1.38) 0.0007 — — 
WC (cm) a 1.07 (1.04, 1.11) <.0001 — — 
1.06 
(1.01, 1.11) 0.0094 
HOMA-IR 1.25 (1.06, 1.49) 0.0100 
0.89 
(0.73, 1.09) 0.2602 
0.94 
(0.77, 1.15) 0.5326 
HDL-c 
(mg/dL) 
0.96 
(0.93, 0.98) 0.0009 
0.97 
(0.94, 1.01) 0.1371 
0.97 
(0.94, 1.01) 0.1133 
LDL-c 
(mg/dL) 
1.01 
(0.998, 1.01) 0.1573 
1.00 
(0.99, 1.01) 0.5891 
1.00 
(0.995, 1.01) 0.4589 
Triglycerides 
(mg/dL) 
1.01 
(1.00, 1.02) 0.0071 
1.00 
(0.995, 1.01) 0.5595 
1.00 
(0.99, 1.01) 0.6878 
DBP 
(mmHg) 
1.02 
(0.999, 1.05) 0.0630 
1.00 
(0.95, 1.05) 0.9498 
1.00 
(0.95, 1.05) 0.9243 
SBP 
(mmHg) 
1.01 
(0.997, 1.03) 0.1187 
1.00 
(0.97, 1.03) 0.9233 
1.01 
(0.97, 1.04) 0.7491 
Drink 8+ 0.39 (0.07, 2.07) 0.2699 
0.27 
(0.04, 2.01) 0.2015 
0.21 
(0.03, 1.67) 0.1383 
Walking 
(hr/week) b 
1.03 
(0.96, 1.09) 0.4502 
1.03 
(0.95, 1.11) 0.5267 
1.04 
(0.97, 1.12) 0.3117 
Past Smoker 0.81 (0.40, 1.65) 0.5631 
0.52 
(0.23, 1.19) 0.1230 
0.52 
(0.22, 1.20) 0.1225 
Current 
Smoker 
0.63 
(0.17, 2.33) 0.4898 
0.92 
(0.20, 4.37) 0.9198 
0.77 
(0.17, 3.55) 0.7345 
TV (≥14 
hrs/week) c 
0.73 
(0.40, 1.32) 0.2912 
0.73 
(0.35, 1.52) 0.3999 
0.78 
(0.38, 1.61) 0.5018 
Anti-
diabetics 
1.84 
(0.69, 4.88) 0.2236 
1.63 
(0.45, 5.91) 0.4576 
1.77 
(0.50, 6.26) 0.3768 
NSAID Use 2.40 (0.71, 8.08) 0.1567 
1.82 
(0.40, 8.31) 0.4382 
1.60 
(0.34, 7.54) 0.5512 
Anti-
hypertensive 
Use 
2.13 
(1.05, 4.33) 0.0355 
1.39 
(0.55, 3.51) 0.4877 
1.19 
(0.47, 3.01) 0.7130 
  a,b,c: Variables that had less than N = 195 for univariable analyses.  
 Waist circumference, N = 193. Walking, N = 191. TV watching, N = 194 
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Table 7. Logistic Regression (Quartiles) 
Baseline 
Variable 
Univariable Analysis 
(N = 98) 
 
Multivariable Analysis 
(BMI, N = 95) 
 
Multivariable Analysis  
(WC, N = 93) 
 
OR 
(95% CI) p 
OR 
(95% CI) p 
OR 
(95% CI) p 
LBP (µg/mL) 1.08 (1.02, 1.14) 0.0124 
1.11 
(1.02, 1.20) 0.0157 
1.09 
(1.01, 1.18) 0.0301 
Age (years) 0.97 (0.93, 1.01) 0.1791 
1.00 
(0.94, 1.07) 0.9461 
0.99 
(0.93, 1.06) 0.8325 
BMI (kg/m2) 1.32 (1.15, 1.51) <.0001 
1.34 
(1.09, 1.64) 0.0059 — — 
WC (cm) 1.09 (1.04, 1.15) 0.0004 — — 
1.07 
(0.999, 1.14) 0.0532 
HOMA-IR 1.44 (1.11, 1.88) 0.0069 
0.96 
(0.66, 1.40) 0.8240 
1.08 
(0.74, 1.59) 0.6823 
HDL-c  
(mg/dL) 
0.94 
(0.90, 0.98) 0.0039 
0.97 
(0.91, 1.03) 0.2880 
0.98 
(0.92, 1.04) 0.4249 
LDL-c  
(mg/dL) 
1.00 
(0.995, 1.01) 0.4269 
1.00 
(0.99, 1.01) 0.9853 
1.00 
(0.99, 1.01) 0.9510 
Triglycerides 
(mg/dL) 
1.01 
(1.00, 1.02) 0.0239 
1.00 
(0.99, 1.01) 0.7990 
1.00 
(0.99, 1.01) 0.7947 
DBP (mmHg) 1.03 (0.999, 1.06) 0.0579 
1.01 
(0.94, 1.09) 0.7764 
1.03 
(0.96, 1.11) 0.3820 
SBP (mmHg) 1.01 (0.99, 1.03) 0.1948 
1.01 
(0.95, 1.06) 0.8323 
1.00 
(0.95, 1.05) 0.8794 
Drink 8+ 0.32 (0.03, 3.18) 0.3306 
0.26 
(0.01, 4.78) 0.3614 
0.13 
(0.004, 3.69) 0.2309 
Walking 
(hr/week) a 
0.96 
(0.88, 1.05) 0.4079 
1.00 
(0.88, 1.14) 0.9919 
1.01 
(0.90, 1.14) 0.8267 
Past Smoker 0.62 (0.24, 1.58) 0.3124 
0.48 
(0.14, 1.63) 0.2397 
0.51 
(0.16, 1.64) 0.2593 
Current 
Smoker 
0.65 
(0.13, 3.11) 0.5857 
0.78 
(0.08, 7.46) 0.8299 
0.58 
(0.07, 4.99) 0.6187 
TV (≥14 
hrs/week) 
0.71 
(0.31, 1.60) 0.4076 
0.85 
(0.28, 2.60) 0.7817 
0.82 
(0.28, 2.40) 0.7127 
Anti-
diabetics 
60.25 
(1.25, 29.14) 0.0256 
6.83 
(0.80, 58.32) 0.0790 
8.14 
(0.97, 68.06) 0.0529 
NSAIDs 2.09 (0.36, 11.97) 0.4083 
1.09 
(0.06, 19.94) 0.9545 
1.08 
(0.07, 16.59) 0.9548 
Anti-
hypertensives 
2.49 
(0.95, 6.52) 0.0644 
1.38 
(0.30, 6.34) 0.6794 
1.07 
(0.23, 5.10) 0.9308 
    a: Walking had N = 97 for univariable analysis 
 
 
 25 
4.0  DISCUSSION 
To the best of our knowledge, our study is the first study to investigate the heritability of 
LBP in any population and the first to investigate longitudinal associations between LBP and liver 
fat in an African Ancestry population. We found that LBP was entirely environmentally 
determined in a group of large Afro-Caribbean families. We also found that higher baseline levels 
of LBP were independently associated with higher liver fat content at follow-up visits in linear 
regression models using BMI as an obesity measure, but that this association was attenuated when 
instead adjusting for waist circumference. Additionally, we found that levels of LBP differed 
between the highest and lowest quartile of liver attenuation. These data help to support the role of 
intestinal bacteria-induced inflammation in the progression of NAFLD. 
Lipopolysaccharide (LPS) is a cell-wall lipid constituent of Gram-negative bacteria10. LPS 
binds to cell-surface receptor toll-like receptor 4 (TLR4) and induces inflammation12. Intestinal 
bacterial-derived LPS can enter the circulation by moving between intestinal epithelial cells or by 
incorporation into chylomicrons38, and its first point of contact is the liver via the hepatic portal 
vein11. Levels of circulating LPS have been shown to increase after eating energy-rich meals38, 
and chronic LPS infusion mimics the weight gain of eating a high fat diet15, linking LPS to 
systemic low-grade inflammation and increased adiposity. 
LBP is an acute phase protein which is responsible for binding to LPS, complexing with 
protein CD14, and ultimately transferring LPS to the TLR412. In the presence of LBP, 
macrophages produced inflammatory cytokines at a 1000-fold lower level of LPS, demonstrating 
the importance of LBP to this pathway39. Importantly, inflammatory cytokines can upregulate 
production of LBP11, suggesting that LBP may serve as a marker of LPS-induced inflammation. 
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There are several limitations to measuring LPS in the blood owing to interference by many 
factors40. LBP can be measured using a simple ELISA, and has been shown to have a good 
correlation with coefficients ≥ 0.617. Therefore, it has widely been used as a surrogate marker for 
LPS-induced inflammation18-22,41. However, given that LBP is produced in response to 
inflammatory cytokines, it can be produced during non–Gram-negative bacterial infections or 
other acute-phase reactions42. 
LBP is constitutively expressed at low levels by liver cells11; however, various genetic 
polymorphisms in LBP may affect protein levels and have functional outcomes. For example, SNP 
1683 C allele (rs2232571; LBP:c.−836T>C) is a CAAT box promoter variant which has been 
associated with higher basal levels of LBP and a 5-fold increase in death by Gram-negative 
bacteremia following a hematopoietic cell transplant43. Another study also found that LBP variants 
were associated with being susceptible to severe sepsis44. Given this knowledge, it is possible that 
our measured LBP levels could also be influenced by genetic factors, thus reducing our claims of 
LBP serving as a biomarker for LPS-induced inflammation. 
Our heritability analysis results suggest that this is not the case in our population. The 
Tobago population is primarily of African descent, with little in- or out-migration and with ~6% 
European admixture (unpublished data). Thus, this makes them a unique population to study using 
large family study genetic analyses. Our analysis shows that LBP has virtually no residual 
heritability, indicating that levels of LBP are due entirely to environmental factors. This would 
suggest that no variants affecting LBP production are to be found in several of the large families 
comprising this Caribbean island population. It has been found that toll-like receptor (TLR) SNPs 
vary regionally and that the high prevalence of a pro-inflammatory variant in TLR4 in sub-Saharan 
African populations is due to a protective advantage against malaria45; additionally, African 
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ancestry individuals from the Cardiovascular Health Study have been found to have a CD14 SNP 
which was associated with lower levels of CD1446. It is possible, then, that familial differences in 
levels of other proteins involved in LPS recognition and subsequent inflammation may be present 
in our population; this will need to be investigated in future work. 
Our findings that LBP was associated with BMI and waist circumference agree with the 
current literature17-21. Obesity is a strong risk factor for NAFLD and has been reported to be present 
in as high as 80% of obese adults47. We found, however, that there were differences in significance 
of covariates in linear regression models when using either BMI or waist circumference (Table 4). 
Waist circumference could be more important predictor than general obesity with regards to liver 
fat accumulation37. Still, it is possible that differences in these models may be due to the difference 
in sample sizes for each model. The waist circumference model had two fewer individuals in it, 
and given that the sample size was small to begin with, this reduction could have an impact. Indeed, 
we found that reducing the BMI model by the same two individuals missing waist circumference 
values changed the significance of LBP to become non-significant (Appendix Table 9). A larger 
sample size after future data release can help to resolve this discrepancy. 
We found that in our cohort that insulin resistance was correlated with liver fat (Table 3) 
and that it was associated with liver fat in univariable linear and logistic regression analyses (Table 
4, Table  6, and Table 7). This is to be expected, as insulin resistance is a common pathological 
feature of NAFLD3,4. However, after adjustment for other covariates, this association became 
insignificant. This may in part be due to the role of LBP in promoting insulin resistance. We have 
previously reported that LBP was associated with insulin resistance in this population21, and this 
finding is also supported by the literature17,41,48,49. TLR4 activation can interrupt insulin signaling 
through insulin receptor substrate (IRS) deactivation and degradation, as reviewed by Lontchi-
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Yimagou et al.50. Mice with hematopoietic cell-specific deletion of Tlr4 fed a high fat diet became 
obese but became more insulin sensitive in hepatic and adipose tissues, demonstrating that 
hematopoietic TLR4 may be necessary for hepatic insulin resistance51. It is possible, then, that 
LBP serves as the promoter of liver insulin resistance which can then lead to liver fat accumulation. 
We report for the first time that levels of LBP are positively and significantly associated 
with longitudinal liver fat infiltration. We also found that levels of LBP can discriminate between 
the highest and lowest quartiles of liver attenuation value. In a mouse model, Lbp−/− mice had less 
diet-induced liver damage than wild-type mice when fed a western-style diet52. LBP has also been 
found to correlate with liver portal and interface inflammation, with myofibroblasts and fibrosis53. 
In humans, LBP has been found to show associations with the incidence or presence of NAFLD22-
24. However, to the best of our knowledge, this is the first study which has looked at a longitudinal 
association between LBP and liver fat. A study by Wong et. al.23 found that LBP was not cross-
sectionally associated with liver fat after adjustment for other factors, and while liver fat was 
measured in a subset of the population at a later time (~1.5–2.5 years later), the authors only 
reported associations with incident NAFLD but not with measures of liver fat. The time between 
our visits was much longer (~10 years), and thus participants may have had greater liver fat 
accumulation. 
Our study has several limitations. First, we are using LBP as a surrogate biomarker for 
LPS-induced inflammation; however, as discussed previously, while it is not an infallible marker 
it is a better alternative than trying to measure LPS directly. Still, our results are limited by a lack 
of acute inflammatory markers. Second, we did not collect extensive dietary data in either the 
family or the cohort populations, and dietary components could independently affect liver fat or 
affect the microbiome. Third, we only investigated heritability of one component of the LPS-
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induced inflammatory pathway. Fourth, the sample size of our cohort population is quite small. 
We are waiting for additional data releases to see if the associations we found can hold in a larger 
population. Fifth, we only were able to adjust for baseline measures of variables and did not have 
baseline levels of liver fat. It is possible that change in levels of liver fat or in levels of LBP may 
be more informative predictors and outcomes. Finally, both of our populations are of Afro-
Caribbean background, and our cohort population is comprised completely of middle-aged and 
older men. African ancestry men have been found to have lower rates of NAFLD than whites or 
hispanics54, and it has been suggested that this could be due to differences in lipid homeostasis55; 
additionally, NAFLD shows a slightly higher prevalence among the elderly compared to younger 
adults, with 15%–30% among the younger and 35.1% in the older56. Thus, our findings may not 
apply to other ethnic groups, ages, or to women. 
In conclusion, we report for the first time an independent association between levels of 
LBP and future liver fat content, and that these LBP levels are likely due to environmental effects 
and not genetics. This association provides one plausible mechanistic role for the effects of the 
intestinal microbiome on liver fat accumulation. The public health significance of this work is in 
the supplying of greater insights into the etiology of NAFLD, an understanding which is necessary 
for effective treatments of NAFLD. Future research will need to be done to confirm these findings 
in our larger population size when data has been released, and these findings will also need to be 
confirmed in other populations of different age, sex, and ethnic background. 
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APPENDIX: TABLES 
Table 8. Comparisons of Cohorts 
Variable 
Tobago Health 
Study Full Cohort 
 
LBP/Liver 
Cohort 
 
Men with Liver 
Scans 
 
Men with LBP 
Measures 
 
N 
Median 
(IQR) 
or N 
(%) 
N 
Median 
(IQR) 
or N 
(%) 
N 
Median 
(IQR) 
or N 
(%) 
N 
Median 
(IQR) 
or N 
(%) 
General and Lifestyle Risk Factors 
Age (years) 2161 57 (50, 67) 195 
53 (48, 
64) 539 
53 (48, 
60) 581 
58 (49, 
67) 
BMI (kg/m2) 2163 
27.02 
(24.39, 
29.94) 
195 
27.03 
(24.59, 
29.56) 
540 
27.04 
(24.65, 
30.02) 
582 
26.90 
(24.54, 
29.46) 
Perceived 
Good Health 2149 
1967 
(91.53) 194 
183 
(94.33) 537 
515 
(95.90) 579 
541 
(93.44) 
Walking 
(hrs/week) 2134 
1.5 (0, 
3.5) 191 
1.5 (0, 
5) 536 
1.25 (0, 
4) 570 
1.5 (0, 
4) 
TV Watching ≥ 
14 hrs/week 2156 
824 
(38.22) 194 
67 
(34.54) 536 
205 
(38.25) 579 
219 
(37.82) 
Any Alcohol 
Consumption 2164 
1315 
(60.77) 195 
113 
(57.95) 540 
346 
(64.07) 582 
348 
(59.79) 
8+ Alcoholic 
Drinks / Week 2168 
140 
(6.46) 195 7 (3.59) 541 
37 
(6.84) 582 
31 
(5.33) 
Previous 
Smoker 2165 
483 
(22.31) 195 39 (20) 541 
116 
(21.44) 582 
126 
(21.65) 
Current 
Smoker 2165 
229 
(10.58) 195 
10 
(5.13) 541 
51 
(9.43) 582 
44 
(7.56) 
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Table 8 (continued) 
 
Prediabetic 2086 376 (18.02) 195 
46 
(23.59) 526 
108 
(20.53) 582 
119 
(20.45) 
Diabetic 2086 438 (21) 195 
29 
(14.87) 526 
65 
(12.36) 582 
121 
(20.79) 
Hypertension 2167 1125 (51.92) 195 
106 
(54.36) 541 
259 
(47.87) 582 
313 
(53.78) 
Cardiometabolic Markers 
LBP (µg/mL)  —  — 195 
20.89 
(16.30, 
27.11) 
—   — 580 
21.35 
(16.84, 
27.21) 
HDL-c 
(mg/dL) 1813 
47.8 
(40.8, 
57) 
195 
48 
(41.1, 
57.1) 
470 
48.6 
(41.1, 
56.8) 
561 
46.9 
(41, 
56.2) 
LDL-c (mg/dL) 1811 
130 
(105.2, 
156.1) 
195 
134.5 
(103.1, 
162.2) 
468 
131.25 
(107.65, 
158.05) 
561 
132.4 
(106.9, 
161) 
Triglycerides 
(mg/dL) 1813 
97 (75, 
131) 195 
103 (77, 
131) 470 
100 (75, 
131) 561 
99 (75, 
135) 
Glucose 
(mg/dL) 2086 
94 (86, 
108) 202 
93 (85, 
105) 526 
92 (84, 
102) 582 
94 (86, 
108) 
Insulin 
(mg/dL) 2083 
11.1 
(8.3, 
15) 
202 
11.1 
(8.3, 
15.9) 
526 
10.8 
(8.3, 
15.4) 
582 
10.6 
(8.2, 
14.8) 
HOMA-IR 2083 
2.72 
(1.91, 
4.02) 
195 
2.75 
(1.85, 
4.11) 
526 
2.63 
(1.82, 
3.97) 
582 
2.68 
(1.88, 
4.00) 
Liver Parameters 
Mean Liver 
Attenuation 
(HU) 
 — —  195 
59.36 
(54.69, 
61.87) 
545 
58.64 
(53.77, 
61.68) 
 — — 
Fatty Liver 
Disease at 
Follow-up 
— — 195 8 (4.10) 545 22 (4.04) — — 
Medications 
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Table 8 (continued) 
 
Antidiabetic 
Medication 2168 
313 
(14.44) 195 
19 
(9.74) 541 
45 
(8.32) 582 
78 
(13.40) 
NSAIDs 
Medication 2168 
187 
(8.63) 195 
13 
(6.67) 541 
31 
(5.73) 582 
50 
(8.59) 
Antihypertensive 
Medication 2167 
486 
(22.43) 195 
42 
(21.54) 541 
96 
(17.74) 582 
132 
(22.68) 
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Table 9. Linear Regression with BMI or WC, N = 188 
Baseline Variable Model with BMI 
Model with Waist 
Circumference 
β (SE) p β (SE) p 
LBP (µg/mL) −10.34 (8.25) 0.0505 −10.30 (8.27) 0.0547 
Age (years) 7.62 (7.97) 0.3828 8.42 (7.98) 0.2424 
WC (cm) — — −11.44 (7.85) 0.0023 
BMI (kg/m2) −16.4 (10.8) 0.0006 — — 
HOMA-IR −12.42 (13.62) 0.4498 −13.43 (13.62) 0.3392 
HDL-c (mg/dL) 5.69 (7.46) 0.6580 5.48 (7.50) 0.6961 
LDL-c (mg/dL) 0.96 (4.71) 0.9933 −2.44 (4.72) 0.8895 
Triglycerides 
(mg/dL) −4.75 (4.6) 0.2727 −4.58 (4.62) 0.3316 
DBP (mmHg) −7.12 (8.68) 0.5814 −7.30 (8.71) 0.5571 
SBP (mmHg) 6.36 (7.36) 0.5213 5.89 (7.40) 0.6147 
Drink 8+ 35.98 (28.76) 0.0518 38.23 (28.95) 0.0226 
Walking (hr/week) 5.34 (9.88) 0.8747 −3.98 (9.88) 0.9479 
Smoking Status 18.15 (20.08) 0.4611 19.50 (20.13) 0.3645 
TV (≥14 hrs/week) 12.89 (21.23) 0.8230 10.87 (21.32) 0.8948 
Anti-diabetics −22.79 (25.35) 0.4683 −24.47 (25.43) 0.3744 
NSAIDs 11.72 (27.02) 0.9351 10.67 (27.09) 0.9514 
Anti-hypertensives −25.9 (22.93) 0.1513 −24.09 (23.01) 0.2526 
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